Glaukos Corporation has completed enrollment in a phase 2 clinical study evaluating GLK-321, an investigational treatment for Demodex blepharitis that uses the company’s iLution drug-delivery platform.

The randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multicenter study enrolled 275 patients at US clinical sites. The trial is evaluating 3 dose levels of GLK-321, with safety, tolerability, and efficacy measures. The primary efficacy end point is the proportion of study eyes achieving elimination of collarettes after 6 weeks of treatment.

GLK-321 is formulated with physostigmine and is applied to the outer surface of the eyelids. The iLution platform uses cream-based formulations intended to provide transdermal delivery of active compounds without eye drops. OM